[1]吴 天.药品集中采购价格与药品费用控制研究[J].卫生经济研究,2018,(12):32-34.
　WU Tian.Research on Centralized Purchasing Price and Drug Cost Control of Medicines[J].Journal Press of Health Economics Research,2018,(12):32-34.
点击复制

药品集中采购价格与药品费用控制研究
分享到：

卫生经济研究[ISSN:1004-7778/CN:33-1056/F]

卷:
期数:
2018年12期
页码:
32-34
栏目:
药械管理
出版日期:
2018-12-04

文章信息/Info

Title:
Research on Centralized Purchasing Price and Drug Cost Control of Medicines
作者:
吴 天1
1.江苏省公共资源交易中心，江苏 南京 210008
Author(s):
WU Tian
Jiangsu Provincial Public Resource Trading Center，Nanjing Jiangsu 210008，China
关键词:
药品集中采购; 药品价格; 药品费用控制
Keywords:
centralized procurement of drugs;  drug prices;  drug cost control
分类号:
R97；R19
文献标志码:
A
摘要:
通过对药品的经济学特征、药品集中采购价格形成机制和药品费用构成因素的分析，认为：价格并非影响药品费用最重要的因素，药品集中采购也不能形成真正合理的价格；应积极发挥医疗保险的作用，加强对医生行为的约束，以实现降低药品价格和控制药品费用不合理增长的目标。
Abstract:
Through the analysis of the economic characteristics of drugs，the formation mechanism of centralized drug purchase price and the components of drug costs，this paper concluded that price was not the most important factor affecting drug costs，and centralized purchasing of drugs can't form a truly reasonable price. To achieve the goal of reducing drug prices and controlling the unreasonable growth of drug costs，we should attach importance to medical insurance and strengthen the constraints on doctors' behavior.

参考文献/References:

[1] Frank R.G, Salkever D.S. Pricing, Patent loss and the market for Pharmaceuticals[J].Southern Economic Journal,1992, 59（2）:165-179.
[2] Chee Ruey Hsieh. Adoption of Pharmaceutical Innovation and the Growth of Drug Expenditure in Taiwan: Is It Cost Effective?[J]. Valure in Health, 2008，11（2）：334-344.
[3] F. R. Lichtenberg. The Impact of New Drug Launches on Longevity: Evidence from Longitudinal Disease-Level Data from 52 Countries, 1982-2001. NBER Working Paper,2003:9754.
[4] 何志高.对当前我国遏制药品费用过快上涨政策的理性思考[J].中国药房，2005,16(18):1364－1366.
[5] 刘娜.药品集中招标采购的利益协调机制研究[D].暨南大学硕士论文，2005：19－21.
[6] 蒋建华. 药品费用的影响因素分析——基于省级数据的实证研究[J].卫生经济研究, 2015(8):30-33.

相似文献/References:

[1]周引德,傅鸿鹏.基层医疗机构药品配备使用情况分析[J].卫生经济研究,2016,(05):38.
[2]赵 静.药品价格改革问题研究[J].卫生经济研究,2016,(07):51.
[3]李银才.药品价格市场形成机制改革研究[J].卫生经济研究,2016,(07):55.
[4]袁 姣,刘杨正,左克源,等.基于药品集中采购的供应链融资模式研究[J].卫生经济研究,2017,(01):50.
[5]黄泽华,潘 越,钭江苑,等.药物经济学在医保决策中的应用[J].卫生经济研究,2017,(03):37.
[6]胡善联.药品购销“两票制”政策的理论和实践[J].卫生经济研究,2017,(04):8.
[7]周 苑,汤质如,刘守明,等.药品集中采购模式研究及问题探讨[J].卫生经济研究,2018,(03):26.
[8]乔家骏,曾旖旎,傅鸿鹏.“两票制”对药企经济运行及药品价格的影响[J].卫生经济研究,2018,(10):61.
　QIAO Jia-jun,ZENG Yi-ni,FU Hong-peng.The Influence of “Two-vote System” on the Economic Operation of Pharmaceutical Companies and Drug Prices[J].Journal Press of Health Economics Research,2018,(12):61.
[9]殷 婷,汤少梁.基于消费者剩余理论的患者药品福利研究[J].卫生经济研究,2019,(02):13.
　YIN Ting,TANG Shao-liang.Research on Patient Drug Welfare Based on Consumer Surplus Theory[J].Journal Press of Health Economics Research,2019,(12):13.
[10]潘 静,王艳翚.区域差异化背景下我国23个省市药价水平比较分析[J].卫生经济研究,2019,(02):49.
　PAN Jing,WANG Yan-hui.Comparative Analysis of Drug Price Levels in 23 Provinces and Cities in China under the Background of Regional Differentiation[J].Journal Press of Health Economics Research,2019,(12):49.

更新日期/Last Update: 2018-12-04